Wednesday, February 10, 2016

Seeking Alpha: Elekta Looking To Get Back On Track

The radiotherapy space has long been a duopoly, but it would seem as though Elekta (OTCPK:EKTAY) is doing all it can to create opportunities for Varian (NYSE:VAR), Accuray (NASDAQ:ARAY), and other players to chip away at its roughly 30% market share. From overly aggressive sales practices to over-reliance on the Gamma Knife, to serious volatility in reported results, not much has gone right over the last three years or so.

On the positive side, Elekta has had a lot of problems but still has that 30% market share and isn't seriously threatened by Accuray at present. What's more, the Atlantic MRI linac combo device could be a big step forward and an opportunity to dominate a market that could be worth about half the company's trailing revenue base. On the negative side, both Varian and Accuray have been picking away at the business, the company has no near-term leverage to the proton beam market, and a lot of credibility and investor goodwill has been chewed up by the company's struggles.

Continue here:
Elekta Looking To Get Back On Track

No comments: